A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Ladiratuzumab-Vedotin (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors Seattle Genetics
- 12 Mar 2018 Planned number of patients changed from 216 to 306.
- 12 Mar 2018 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.
- 12 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History